The Society for the Immunotherapy of Cancer (SITC) is offering a nine-part webinar series focused on specific topics within cancer immunotherapy, along with a live, interactive Q&A with renowned experts. This comprehensive series is perfect for early-career scientists to established researchers, industry and members of the investment community, plus clinicians and other researchers interested in learning more about the latest advances in this rapidly evolving field.
MILWAUKEE, May 18, 2022 /PRNewswire-PRWeb/ -- The Society for the Immunotherapy of Cancer (SITC) is offering a nine-part webinar series focused on specific topics within cancer immunotherapy, along with a live, interactive Q&A with renowned experts. This comprehensive series is perfect for early-career scientists to established researchers, industry and members of the investment community, plus clinicians and other researchers interested in learning more about the latest advances in this rapidly evolving field.
Open registration is available now at sitcancer.org/DeepDive, and with the purchase of four webinars, participants can add the remaining five webinars at no additional cost. This includes access to the enduring materials for each webinar.
This is the second year SITC has presented "Targets for Cancer IO: A Deep Dive Series" to cancer researchers seeking focused, yet comprehensive investigative research on a particular cancer immunotherapy topic. Where the series provides real, unique value is bringing a global approach to a single topic.
"Despite the massive growth in scientific meetings in our field, this series stands out in that each webinar is totally focused on one particular topic, rather than a more diffuse overview of several related topics," shared Dan Chen, MD, PhD, co-organizer of the series. "Then, its interactive approach to discussion allows all participants to bounce ideas off the most renowned researchers in the field."
Dr. Chen notes that he's not seen panel discussions as open as those conducted in the Deep Dive series. "If you join live – and I encourage you to do so – there's quite a bit of interaction, both through chat and live question-and-answer from researchers like James P. Allison, PhD, FAIO; Lewis L. Lanier, PhD; Alan J. Korman, PhD, FAIO; and Aaron M. Ring, MD, PhD, just to name a few."
Topics for this year's series include:
- LAG-3 Biology and Current Clinical Results
- Engineered Cytokines in Cancer Immunotherapy
- TIL Therapies
- Targeted Systemic Delivery of Innate Immune Activators
- Scientific Basis of B-cell Modulation for Anti-Tumor Immunity and Reduction of ICI Toxicity
- iPSC Derived Cell Therapies
- Enhanced CTLA-4 Blockade
- TCR Based Therapeutics
- NK Cell Engagers
"I really hope you get a chance to join us live this year," Dr. Chen concluded. "I'm looking forward to seeing you there."
Targets for Cancer Immunotherapy: A Deep Dive Series begins June 13. To find out more about the series, please contact Sara Hathaway at [email protected].
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected]
SOURCE Society for Immunotherapy of Cancer
Share this article